23 These authors contributed equally to this work. 24 2 26 ABSTRACT 27 Substance Use Disorder (SUD) is a major public health concern affecting an estimated 22.5 28 million individuals in the United States. The primary aim of this study was to characterize 29 psychological pain in a cohort of patients participating in outpatient substance abuse 30 treatment. A secondary aim was to determine the relationships between pre-treatment 31 assessments of psychological pain, depression, anxiety and hopelessness with treatment 32 retention time and completion rates. Data was analyzed from 289 patients enrolled in an 33 outpatient community drug treatment clinic that provides mental healthcare to the 34 underserved. A previously determined threshold score on the Mee-Bunney Psychological 35 Pain Assessment Scale (MBP) was utilized to group patients into high and low-moderate 36 scoring subgroups. The higher pain group reported increased levels of anxiety, 37 hopelessness and depression compared to those in the low-moderate pain group.
include categories such as current and past (within 3 months) psychological pain levels, 102 intensity, and tolerance (e.g., how much psychological pain can you tolerate before it 103 becomes unbearable?). We previously documented higher levels of psychological pain in 104 patients with major depressive episodes (MDEs) compared to healthy controls (10) where a 105 secondary finding included a significant correlation between psychological pain and 106 suicidality scores obtained from the Suicide Behavior Questionnaire (28). In a follow-up 107 study we examined psychological pain as a pre-treatment risk indicator for suicidality and 108 serious suicide attempts in U.S. Veterans admitted to a suicide prevention program. Our 109 findings showed that of all the assessments including depression, hopelessness and 110 impulsivity, psychological pain accounted for the most shared variance with suicidality as 111 measured by the Columbia Suicidality Severity Rating Scale (C-SSRS). Using the previously 112 tested MBP threshold score of MBP≥32 [defined as 0.5 SD above the mean of the MDE 113 patients (10)],we identified a subgroup of patients (24/57) scoring high for psychological 114 pain. At a 15-month follow-up, 9 of the 24 patients had a serious suicidal event (as defined 115 by criteria on the C-SSRS). Of those scoring above 32 on the Mee-Bunney scale, 7/9 would 116 have died if not found and one patient completed suicide. Taken together, these results 117 showed that high psychological pain increased the risk for suicidal ideation and serious 118 suicidal events. In addition, they provided preliminary evidence that stratifying patients by 119 psychological pain scores could aid in identifying those experiencing an elevated risk for 120 negative clinical outcomes.
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In this study, we hypothesized that psychological pain would correlate with ratings 122 of depression, anxiety and hopelessness consistent with our previous findings in other 123 psychiatric populations. In addition, we tested whether high levels of psychological pain 124 would correlate with an elevated risk for poorer treatment outcomes (i.e., treatment 125 retention times (LOS) and completion rates) compared with lower MBP scoring patients. 
METHODS

127
140
Healthcare Agency approved the study and waived informed consent due to the minimal 141 risk associated with a retrospective chart review. We carefully protected the identity of the 142 patients by assigning each patient a numerical code to ensure privacy. Research personnel 143 conducting chart reviews were blind to the study protocol. 
196
Clinical ratings: As described in Table 2 scoring of clinical assessments for all patients 197 indicated low levels of depression (BDI), anxiety (BAI) and hopelessness (BHS).
198
Psychological pain scores were in the low-moderate range based on previous studies in 199 normal and depressed populations (Mee, et al., 2011) . Determination of Cronbach's alpha 
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Additionally, we found evidence that elevated pretreatment psychological pain is associated 325 with negative treatment outcomes such as diminished treatment retention time (LOS) and 326 reduced likelihood for program completion. We chose program completion as a proximal 327 indicator of overall treatment outcome although we did not have follow-up for abstinence.
328
Dropout was the most frequent treatment outcome for the SACS patients. This 329 observation agrees with data from the Treatment Episode Data Set (TEDS) published by 330 SAMHSA (32). Our patient population exhibited dropout rates somewhat higher than many 331 programs reported to the TEDS nationwide. It is possible that this was in part due to a high 332 proportion (73.7%) of our patients reporting methamphetamine dependence. Data from a 333 similar region in Los Angeles, California found that methamphetamine abusers were likely 334 to continue drug use during initial entry into the program, a factor which was thought to 335 contribute to the relatively high attrition rate (51%) during the first few weeks of treatment 336 (33) . Another potential factor is that many of the patients were disadvantaged. We did find 
